Abstract The present study sought to examine: (1) the prevalence and correlates of biologically confirmed Hepatitis C (HCV) and (2) the prevalence and correlates of prior HCV diagnosis and an unmet need for HCV treatment, among a community residing sample of drug users. The current study used a subset of HCV tested participants from the larger NEURO-HIV Epidemiologic Study from Baltimore, Maryland (M age = 34.81, SD = 9.25; 46 % female). All participants were tested for HCV at baseline. Selfreport was used to assess awareness of an HCV diagnosis and participation in treatment. Of the 782 participants tested for HCV, 19 % reported having received an HCV diagnosis in the past while 48 % tested positive for HCV. Only 6 % reported having received treatment for any form of hepatitis. Of those who tested HCV positive, 63 % reported never being diagnosed, and only 13 % received any treatment for HCV. We found that only 35 % of those who reported a prior HCV diagnosis received any treatment. The findings regarding lack of HCV awareness and diagnosis were considerable as expected. These deficits suggest that there are numerous gaps in patients' knowledge and beliefs regarding HCV that may interfere at multiple steps along the path from diagnosis to treatment. This study clearly demonstrates that a critical need exists to improve public knowledge of HCV risk factors, the need for testing, and the availability of effective treatment.
Introduction
Hepatitis C (HCV) is a significant public health issue. In the US, HCV infection is the most prevalent chronic blood borne infection and is the leading cause of hepatocellular carcinoma and liver transplant [1] [2] [3] [4] . Current estimates of the economic impact of the disease are alarming. The health care costs are estimated at $360 million annually to treat currently infected patients [5] .
Chronic HCV infection can remain asymptomatic for years, hence under diagnosis of HCV remains a significant challenge [6] . Underdiagnosis of HCV is a significant public health problem which contributes to large proportions of HCV infected people being unaware of their disease status [1, 7, 8] . Approximately 50-75 % of the estimated 5.2 million HCV-positive individuals in the United States are unaware of their diagnosis [9] [10] [11] . The high prevalence of HCV and equally high prevalence of morbidity and mortality that occurs when the disease is undetected and untreated led the CDC to its recent recommendation that all adults born between 1945 and 1965 be tested [12] . This recent recommendation complemented the longstanding recommendation to regularly test highrisk groups. However, under diagnosis remains a significant problem, especially among high risk populations. Therefore, we need to better understand correlates associated with under diagnosis of HCV in high risk groups.
Since 1998, the CDC has recommended routine screening for persons at risk for HCV, including persons with a history of injection drug use and recipients of blood transfusions prior to 1992 [13] . However, due to patient and system obstacles, screening levels have fallen short of this recommendation. This leaves a large proportion of infected individuals unaware of their HCV status and demonstrates the challenges and shortfalls of our current screening strategies [6, 14, 15] . Though there is strong evidence that HCV infection is under diagnosed, there is very limited understanding of the factors influencing under diagnosis among high risk populations. A greater understanding of factors associated with lack of awareness of HCV diagnosis would enable us to address disparities in HCV screening and diagnosis.
A consequence of inadequate screening and detection of HCV infection is that most infected with HCV do not receive needed care such as education, counseling or medical monitoring [16] . In addition, although effective treatments are available, lack of awareness leaves those most in need of treatment with an unmet need for treatment [17] . Although extant literature has documented that many of those diagnosed do not receive needed treatment, few prior studies have measured the unmet need for treatment among those diagnosed.
The current study sought to address these gaps in our understanding of diagnosis and treatment of HCV in a community residing sample of drug users in Baltimore City, a population at high risk of HCV infection. Therefore, the present study sought to examine (1) the prevalence and correlates of biologically confirmed Hepatitis C (HCV) and (2) the prevalence and correlates of prior HCV diagnosis and unmet need for HCV treatment, among those with biologically-confirmed HCV.
Methods

Study Design
Data for this study were obtained from the baseline assessment of the NEURO-HIV Epidemiologic Study. This study was approved by the University of Florida's Institutional Review Board and has received annual renewals. The baseline assessment was designed to examine neuropsychological and social-behavioral risk factors of HIV, hepatitis A, hepatitis B, and hepatitis C among both injection and non-injection drug users. In order to be eligible for participation in the parent study, participants had to be 18 and older and report use of non-injection and/or injection drugs in the past 6 months. Recruitment strategies for participation included advertisements in local newspapers, street outreach, and referrals from local service agencies. Participants were paid $45 for the baseline assessment. Participants provided written informed consent and completed a face to face HIV Risk Behavior Interview. Blood and urine samples were also collected at the baseline assessment. Blood was drawn by a phlebotomist and tested for HIV, hepatitis A, B, and C. Urine samples were tested for the presence of drugs. Participants were subsequently notified of their HIV and/or viral hepatitis status and were referred to drug treatment and social services for counseling with respect to their blood and urine analysis results.
Measures
Biological Measures
Biologically Confirmed HCV Blood samples were taken at baseline and HCV antibody testing was performed. HCV antibodies are assessed by enzyme immunoassays (either EISA 2.0, Abbot or ELISA 3.0, Ortho Diagnostic Systems, Inc Raritan, NJ. Reactive sera were then re-tested by RIBA 3.0 strip immunoblot assay (Chiron) in order to confirm diagnosis.
Biologically Confirmed HIV Blood samples were taken at baseline and HIV antibody testing was performed standard ELISA screening and confirmatory Western Blots.
Urinalysis Urine samples were collected from all participants immediately following informed consent. Urine was analyzed for the presence of drugs including opiates, cocaine, cannabinoids, amphetamines, methamphetamines, methadone, PCP, barbiturates, benzodiazepines, MDMA, and oxycodone.
Self-report Measures
HIV Risk Behavior Interview Self-report measures were collected using the HIV Risk Behavior Interview a detailed behavioral assessment of drug use and sexual practices. This assessment was adapted from a similar interview used in the REACH and ALIVE studies [18, 19] . Questions addressed demographic, educational, medical and neuro developmental variables along with a detailed assessment of lifetime and recent drug use and sexual practices.
Self-report HCV Status Participants were asked ''Have you ever been told by a Health Professional that you had Hepatitis?'' ''What type of Hepatitis were you told you have (response choices: Hepatitis A, Hepatitis B, Hepatitis C, Unknown Hepatitis)?'' Those who responded yes to both ''ever told you had Hepatitis'' and ''Hepatitis C'' were coded as 1; those responded negatively to both or were diagnosed with a different type of hepatitis were coded as 0.
HCV Treatment Participants who responded yes to ''ever been told you have Hepatitis C'' were then asked ''Was treatment given?''; Those who responded yes were coded as a 1 and those who responded no were coded as 0.
Demographics Study demographic questionnaire include questions regarding gender, race, education, marital status, source of income, and stability of housing resources.
Injection Drug Risk Behaviors Participants were asked: ''Have you ever used a needle that you know someone else used?''; ''Have you ever backloaded?''; ''Have you ever shared a cooker?''; ''Have you ever shared cotton?''; and ''Have you ever shared rinse water?'' Those who endorsed any of the five drug risk behaviors were then coded as a 1 and those who did not endorse any of those behaviors were coded as 0.
Data Analysis
To meet study aims, descriptive statistics were used to calculate frequencies, means, and percentages for each variable of interest. The sample was divided into two groups: those who tested positive for HCV and those who tested negative. Chi square (v 2 ) and t test analyses compared the two groups on demographic and predictor variables of interest. We then examined the subset of HCV-positive participants. Frequencies, means, and percentages for each variable of interest were calculated in order to examine differences between those who reported being given a positive HCV diagnosis versus those who reported never receiving an HCV diagnosis. Logistic regression analyses were then conducted to assess the influence of demographic and relevant behavioral variables in relation to self-reported HCV diagnosis. Descriptive data analyses and regression analysis were performed using IBM SPSS Statistics 21 (2013).
Results
Sample Characteristics
The current study includes a subset of the larger study consisting of men and women who were HCV tested (n = 782). Of excluded cases the only significant demographic differences was that sixty-six percent of those missing an HCV test were female. Table 1 shows a complete summary of participant demographics for the current sample. The study sample was 36 % white and 60 % Black/African American, and 4 % other. Fifty-four percent of the sample was male, with 40 % having completed high school or equivalent. The majority of the sample, 67 %, was single-never married. In the past 6 months, 19 % of the sample reported being homeless, 51 % reported receiving public assistance and 40 % reported having money from a regular job. The sample ranged in age from 18 
Demographics Stratified by HCV Status
Frequency distributions for demographic and study variables for the entire sample were stratified by biologically confirmed HCV status (Table 1) There were no differences between the two groups in receipt of public assistance, homelessness, biologically confirmed drug use, seeking help for emotional/behavioral problem or seeking help for a physical/medical illness.
Prevalence and Correlates of HCV Diagnosis, Among Those Infected with HCV
Of those who tested HCV positive 63 % reported never being diagnosed (Fig. 1) . We then examined the characteristics of those who tested positive for HCV and reported receiving an HCV diagnosis versus those who reported not receiving any diagnosis (Table 2) . Using logistic regression analyses we examined the association between demographic and drug risk behavior variables as predictors of self-reported HCV diagnosis. We found that age, gender, education, marital status, homelessness, public assistance, and HIV status were not significantly associated with self-reported HCV diagnosis. African Americans were less (AOR = .525, 95 % CI = .279-.985, p = .04) likely to self-report an HCV diagnosis than whites; those who self-reported seeking help for an emotional or behavioral problem were two times more likely to self-report (AOR = 2.11, 95 % CI = 1.29-3.74, p = .003) an HCV diagnosis than those who did not seek care; and those who engaged in drug risk behaviors were almost 5 times (AOR = 4.90, 95 % CI = 2.71-8.86, 
Unmet Need for HCV Treatment
Of those who reported an HCV diagnosis, 35 % reported receiving treatment. Using logistic regression analysis we examined differences in demographic and drug risk variables for those who reported receiving treatment versus those who reported they did not receive treatment; however no significant differences were found between these groups.
Discussion
The findings regarding HCV prevalence and lack of awareness were considerable as expected. Of the 782 drug users tested for HCV 48 % were HCV-positive. These findings are similar to other high-risk groups. Urban homeless in San Francisco had an infection rate of 73 %; HIV-positive veterans on antiretroviral treatment had a 37 % HCV infection rate; and former heroin addicts in treatment had a 26 % infection rate [20] [21] [22] . Interestingly, HIV infection in the current sample was 11 %, and for those infected with HCV the rate of HIV infection was 14 %, significantly lower than expected given the shared routes of transmission. Of those infected with HCV in the present study, 63 % were unaware of their positive HCV status. These findings suggest that current screening practices are not reaching those at highest risk, leaving a significant number of infected individuals unaware of their diagnosis and need of treatment.
The literature indicates that patient knowledge gaps and beliefs may interfere at multiple steps along the path from diagnosis to treatment. In a sample of HCV? injection drug users, only 22 % reported understanding that HCV is curable, and in a sample of HIV? women, 58 % did not have an opinion on the effectiveness of HCV treatment [16, 23] . Due to a combination of provider judgment and patient beliefs, only 21 % of HCV? patients had a conversation about treatment with their physician. Of those that discussed treatment, 30 % started treatment [23] . Similarly, we found that only 35 % of those who reported receiving an HCV diagnosis received any treatment. Among a sample of HCV-infected injection drug users, the most common reasons for refusing or deferring treatment included treatment-related perceptions (e.g., the side effects are bad), lack of perceived need for treatment, and competing priorities [23] . Common barriers to HCV screening cited by physicians include: other medical complaints that command priority during time-constrained appointments; demonstrated patient noncompliance; co-morbidities that are contraindicated for antiviral treatment; and patients' financial barriers to affording specialist care [24] . Access to a physician and attendance at follow-up appointments is essential for both screening and receiving a diagnosis. In addition to the financial and transportation challenges to completing an initial appointment, patient no-show at screening follow-up appointments means that many HCV-positive individuals do not receive their diagnosis or counseling [25, 26] .
The implementation of oral swab, rapid HCV screening could reduce many of the challenges of diagnosing infected individuals. Without a need for a follow-up visit to receive screening results, more individuals could learn their HCV status. Additionally, the oral test may attract individuals with concerns about undergoing a blood test (e.g., IDU's worried about locating a usable vein) [25, 27] . Diagnosis, coupled with counseling about disease management, risk reduction practices to limit spread to others, and referral to treatment providers can begin to bridge the gap in HCV status awareness and treatment initiation.
While negative provider evaluation of a patient's eligibility for treatment, based on the presence of medical and psychiatric co-morbidities or illicit drug use, may prevent specialist referral, Morrill et al. [28] found through medical record reviews and physician interviews that these cited reasons did not correlate with actual patients' treatment status [28, 29] . Increasing evidence suggests that individuals with contraindicated conditions associated with decreased adherence to medical treatments, such as depression, can have successful outcomes with antiviral therapy under proper management [30] . Similarly, Cohen et al. [16] found that a majority of the women who were referred for liver biopsy or HCV treatment did follow physician recommendations despite ongoing poverty, HIV infection, and substance use [16] .
Our data indicates that those who have engaged in drug risk behaviors are more likely to be aware of their positive HCV status. Those who self-reported an HCV diagnosis were 5 times more likely to acknowledge engaging in drug risk behaviors during their lifetime. Programs that test people who inject drugs (PWID) where they receive services may be contributing to these results and serve as an effective method of identifying and educating those with HCV infection [31] . Through needle exchange programs (NEP), those who inject drugs may be tested at the site where they receive services. In addition, NEP's also provide participants with needed education about risk behaviors and its relationship to HCV disease. While it was a small subset of the current sample, those at greatest risk and those who encountered the healthcare system were the most likely to be aware of their HCV status. This supports the possible effectiveness of increasing public awareness regarding risk factors and testing sources for HCV.
These findings should be evaluated in light of the study's limitations. Self-report was used to determine treatment received, and it does not account for those referred who did not follow-up. However, this study clearly demonstrates that a critical need exists to improve public knowledge of HCV risk factors, the need for testing, and the availability of effective treatment.
